Successfully Filing An IND Using Single Cell Cloning System

Biotheus Inc. was granted an IND in March 2020 for its bispecific therapeutic asset, PM8001. Regulatory approval was attained with help from the Solentim VIPS™ system for single cell cloning and clonality reporting. Because of the ease of use and reliability of the VIPS, valuable time was freed up as well as resources to help with platform development and to support the discovery team for other R&D activities. 

A system like VIPS is important for a small biotech start-up like Biotheus that needs to streamline and accelerate their pipeline development and push multiple lead candidates through to CHO pool generation and cell line selection.